all report title image
  • Published On : Dec 2020
  • Code : CMI4321
  • Industry : Pharmaceutical
  • Pages : 160
  • Formats :

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease. The increasing incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) among the aging population is expected to boost the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth. For instance, according to an article published by the World Heart Federation in August 2019, wild- form of transthyretin amyloid cardiomyopathy (ATTR-CM) is a more common type and usually affects men after the age of 60, and hereditary transthyretin amyloidosis (hATTR) occurs in people in their 50s and 60s.

The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 748.80 million in 2020 and is expected to exhibit a CAGR of 31.1% during the forecast period (2020-2027).

Figure 1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Region, 2020

Transthyretin Amyloid Cardiomyopathy Treatment  | Coherent Market Insights

Ongoing research and development activities are expected to propel growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Major players in the market are focused on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment, which is expected to boost the market growth during the forecast period. For instance, in January 2020, Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., collaboratively initiated CARDIO-TTRansform Phase III cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

However, lack of diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by the Amyloidosis Foundation, in 2016, among the two type of transthyretin amyloid cardiomyopathy (ATTR-CM), wild type transthyretin amyloidosis (wtATTR) is difficult to diagnose than hereditary transthyretin amyloidosis (hATTR) as there is no family history or genetic marker for the disease.

CMI table icon

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 748.80 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 31.1% 2027 Value Projection: US$ 4,984.58 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR).
  • By Drug Type: Transthyretin Stabilizers, Nonsteroidal anti-inflammatory drugs (NSAID), RNAi therapy, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.

Growth Drivers:
  • The rising incidence of transthyretin amyloid cardiomyopathy (ATTR-CM)
  • Ongoing research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatments
Restraints & Challenges:
  • Lack of diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM)
  • Lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM)

Figure 2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Type 2020

Transthyretin Amyloid Cardiomyopathy Treatment  | Coherent Market Insights

Ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in North America are expected to boost the market growth.

North America is expected to hold dominant position in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market owing to the ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in the region. For instance, in November 2020, Intellia Therapeutics, Inc. announced that the first patient has been treated with NTLA-2001, CRISPR/Cas9 technology, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR).

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market during the forecast period.

Key Players

Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. among others.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.

Market Dynamics

Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).

However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.

Key features of the study:

  • This report provides in-depth analysis of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment  market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment  market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Detailed Segmentation:

  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type:
    • Hereditary Transthyretin Amyloidosis (hATTR)
    • Wild Type Transthyretin Amyloidosis (wtATTR)
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type:
    • Transthyretin Stabilizers
    • Nonsteroidal anti-inflammatory drugs (NSAID)
    • RNAi therapy
    • Others
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region:
    • North America
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal anti-inflammatory drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal anti-inflammatory drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Hereditary Transthyretin Amyloidosis (hATTR)
        • Wild Type Transthyretin Amyloidosis (wtATTR)
      • By Drug Type:
        • Transthyretin Stabilizers
        • Nonsteroidal Anti-Inflammatory Drugs (NSAID)
        • RNAi therapy
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline Plc.
    • Eidos Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals
    • Prothena Corporation plc
    • Intellia Therapeutics, Inc.
    • Corino Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to exhibit a CAGR of 31.1% during the forecast period (2020-2027).
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 748.80 million in 2020.
Rising incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) and ongoing research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) is favoring the market growth.
The transthyretin stabilizers drugs segment is expected to be the leading segment in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market during the forecast period (2020-2027).
North America transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market holds the largest market share in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo